Preclinical discovery and development of maraviroc for the treatment of HIV
Nema prikaza
Autori
Veljković, Nevena V.Vučićević, Jelica
Tassini, Sabrina
Glišić, Sanja
Veljković, Veljko
Radi, Marco
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Introduction: Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIVs entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmi...ssible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.
Ključne reči:
antiretroviral therapy / CCR5-receptor antagonist / entry inhibitor / HIV-1 / maravirocIzvor:
Expert Opinion on Drug Discovery, 2015, 10, 6, 671-684Finansiranje / projekti:
- Primena EIIP/ISM bioinformatičke platforme u otkrivanju novih terapeutskih targeta i potencijalnih terapeutskih molekula (RS-MESTD-Basic Research (BR or ON)-173001)
- Sinteza, kvantitativni odnos između strukture i dejstva, fizičko-hemijska karakterizacija i analiza farmakološki aktivnih supstanci (RS-MESTD-Basic Research (BR or ON)-172033)
- European COST Action (GLISTEN) [CM1207], Chiesi Foundation
DOI: 10.1517/17460441.2015.1041497
ISSN: 1746-0441; 1746-045X
PubMed: 25927601
WoS: 000355006600008
Scopus: 2-s2.0-84929887776
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Veljković, Nevena V. AU - Vučićević, Jelica AU - Tassini, Sabrina AU - Glišić, Sanja AU - Veljković, Veljko AU - Radi, Marco PY - 2015 UR - https://vinar.vin.bg.ac.rs/handle/123456789/558 AB - Introduction: Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIVs entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals. T2 - Expert Opinion on Drug Discovery T1 - Preclinical discovery and development of maraviroc for the treatment of HIV VL - 10 IS - 6 SP - 671 EP - 684 DO - 10.1517/17460441.2015.1041497 ER -
@article{ author = "Veljković, Nevena V. and Vučićević, Jelica and Tassini, Sabrina and Glišić, Sanja and Veljković, Veljko and Radi, Marco", year = "2015", abstract = "Introduction: Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIVs entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.", journal = "Expert Opinion on Drug Discovery", title = "Preclinical discovery and development of maraviroc for the treatment of HIV", volume = "10", number = "6", pages = "671-684", doi = "10.1517/17460441.2015.1041497" }
Veljković, N. V., Vučićević, J., Tassini, S., Glišić, S., Veljković, V.,& Radi, M.. (2015). Preclinical discovery and development of maraviroc for the treatment of HIV. in Expert Opinion on Drug Discovery, 10(6), 671-684. https://doi.org/10.1517/17460441.2015.1041497
Veljković NV, Vučićević J, Tassini S, Glišić S, Veljković V, Radi M. Preclinical discovery and development of maraviroc for the treatment of HIV. in Expert Opinion on Drug Discovery. 2015;10(6):671-684. doi:10.1517/17460441.2015.1041497 .
Veljković, Nevena V., Vučićević, Jelica, Tassini, Sabrina, Glišić, Sanja, Veljković, Veljko, Radi, Marco, "Preclinical discovery and development of maraviroc for the treatment of HIV" in Expert Opinion on Drug Discovery, 10, no. 6 (2015):671-684, https://doi.org/10.1517/17460441.2015.1041497 . .